Alx Oncology Holdings (ALXO) Receivables - Accured (2022 - 2024)

Alx Oncology Holdings (ALXO) reported Receivables - Accured of $5.0 million for Q2 2024, up 2647.25% sequentially from $182000.0 in Q1 2023.

Alx Oncology Holdings (ALXO) Receivables - Accured (2022 - 2024) Analysis & Trends

Alx Oncology Holdings (ALXO) has 3 years of Receivables - Accured data on file, last reported at $5.0 million in Q2 2024.

For the quarter ending Q2 2024, Receivables - Accured changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2024 stood at $5.0 million (changed N/A YoY), and the FY2022 full-year result was $78000.0, changed N/A from the prior year.
Receivables - Accured improved to $5.0 million in Q2 2024, from $182000.0 in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of $5.0 million in Q2 2024 to a low of $48000.0 in Q3 2022.
A 3-year average of $1.3 million and a median of $130000.0 in 2022 frame the typical range for Receivables - Accured.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Alx Oncology Holdings	211.24 Mn	211.24 Mn	-	-

Download Data